FindTrial
Sign In

A Phase II Trial of Gefitinib Monotherapy in Elderly Chemo-naïve Patients with Advanced Non–Small Cell Lung Cancer

A Phase II Trial of Gefitinib Monotherapy in Elderly Chemo-naïve Patients with Advanced Non–Small Cell Lung Cancer - A Phase II Trial of Gefitinib Monotherapy in Elderly Chemo-naïve Patients with Advanced Non–Small Cell Lung Cancer

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000118
Enrollment
60
Registered
2005-09-06
Start date
2004-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Gefinitib daily administration

Sponsors

LOGIK
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Histologically or cytologically confirmed NSCLC Stage IIIB/IV No prior treatment Measurable disease ECOG PS 0-2 Adequate organ function Age ≥75 Written informed consent

Exclusion criteria

Exclusion criteria: Past history of drug hypersensitivity SVC syndrome Pleural or pericardial effusion that required drainage Active infection Interstitial pneumonia or active lung fibrosis Symptomatic brain metastasis Active concomitant malignancy Uncontrolled diabetes Uncontrolled heart disease.

Design outcomes

Primary

MeasureTime frame
response rate—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026